KI-Beratung Beta
Vor Ort
Merkzettel Warenkorb
Produktbild: Advancement in CAR T-Cell Therapy in Tumors
- 12%

Advancement in CAR T-Cell Therapy in Tumors Current Challenges and Future Directions

12% sparen

192,99 € UVP 219,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

This contributed volume provides a comprehensive overview of CAR T-cell therapy, focusing on its application in solid tumors, an area where treatment success has been more elusive. While CAR T-cell therapy has revolutionized the treatment of hematologic malignancies, its potential in solid tumors remains...

Beschreibung

This contributed volume provides a comprehensive overview of CAR T-cell therapy, focusing on its application in solid tumors, an area where treatment success has been more elusive. While CAR T-cell therapy has revolutionized the treatment of hematologic malignancies, its potential in solid tumors remains a frontier of intense research and development. This volume bridges the knowledge gap by addressing both the successes and challenges faced by researchers and clinicians in this evolving field.


The chapters cover topics such as the design of next-generation CAR T-cells, novel targets for solid tumors, and the integration of CAR T-cell therapy with other immunotherapeutic strategies. Readers will discover cutting-edge techniques like CRISPR-mediated gene editing, bispecific CARs, and synthetic biology. The book also explores critical questions about manufacturing challenges, regulatory hurdles, and clinical trial outcomes, providing a holistic view of CAR T-cell therapy. Contributions from leading experts in oncology, immunology, and molecular biology offer a multidisciplinary perspective, making this book a valuable resource for understanding the molecular and clinical dynamics of CAR T-cell therapy.


This book is designed for a diverse audience, including researchers, clinicians, and industry professionals involved in cancer research, immunotherapy, and clinical applications. It is also a key reference for graduate and postgraduate students in fields like oncology, immunology, and biotechnology. By offering a comprehensive analysis of the technical, clinical, and regulatory aspects of CAR T-cell therapy, this book serves as a critical resource in the advancement of cancer treatment.

Portrait


Dr. Umesh Kumar
is currently serving as Associate Director in Chandigarh University, Mohali, Punjab. He has been a Professor and Head, Research Cell in the Department of Biosciences at IMS Ghaziabad (University Courses Campus), Ghaziabad, Uttar Pradesh. He also worked as a Scientific Officer in the Department of Biochemistry at the University of Delhi. His research interests encompass a range of topics, including the molecular diagnosis of cervical cancer, the molecular epigenetics of breast carcinogenesis, CAR T-cell therapy, mesenchymal stem cells, epithelial ovarian carcinoma, and tumor virology. 



Dr. Anil Kumar
is presently working as Staff Scientist in the National Institute of Immunology, New Delhi. His research interest focuses on understanding the link between gut microbiota and human cancer as well as how the result of the investigation may be helpful to devise strategies to develop gut bacteria/metabolite-based adjuvant immunotherapy for the treatment of colorectal cancer.His research group is also working on exploring the anticancer potential of gut microbiota derived metabolites for cancer treatment. He had participated in the development of biosensors which have been transferred to industry. In 2012, one of his patents has been selected for CSIR Technology Award 2012 and other US patent won Merck Millipore India Innovation Award 2012.



Dr. Deepak Parashar
is an Assistant Professor in the laboratory of Siegfried Janz in the Division of Hematology and Oncology, Department of Medicine, at the Medical College of Wisconsin (MCW), Milwaukee. His long-term research interests involve the development of a comprehensive understanding of key developmental pathways and how alterations in gene expression contribute to human cancer. His academic training and research experience have provided him with an excellent background in multiple biological disciplines including molecular biology, biochemistry, and genetics. 

Produktdetails

Einband

Gebundene Ausgabe
Erscheinungsdatum

03.01.2026
Abbildungen

XIX, 332 p. 28 illus., 27 illus. in color.
Herausgeber Umesh Kumar + weitere

Produktdetails

Einband

Gebundene Ausgabe
Erscheinungsdatum

03.01.2026
Abbildungen

XIX, 332 p. 28 illus., 27 illus. in color.
Herausgeber
Verlag Springer Singapore
Seitenzahl

332
Maße (L/B/H)

24,1/16/2,5 cm
Gewicht

642 g
Auflage

1. Auflage
Sprache

Englisch
ISBN

978-981-9536-27-6
Herstelleradresse

Springer-Verlag GmbH
Europaplatz 3
69115 Heidelberg
DE

Email: ProductSafety@springernature.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: Advancement in CAR T-Cell Therapy in Tumors

  • Chapter 1: History and Evolution of CAR T-Cell Therapy.- Chapter 2: CAR T-Cell Therapy: Basic Principles and Mechanisms.- Chapter 3: Engineering CAR T-Cells: Advances in Vector Design and Gene Editing.- Chapter 4: Optimizing CAR T-Cell Efficacy: Enhancing Proliferation, Persistence, and Memory.- Chapter 5: Clinical Success of CAR T-Cells in Hematologic Cancers: Lessons from Leukemia and Lymphoma.- Chapter 6: Adverse Effects of CAR T-Cell Therapy and Management: Cytokine Release Syndrome and Neurotoxicity.- Chapter 7: Overcoming Challenges of CAR T-Cell Therapy in Solid Tumor Microenvironments.- Chapter 8: From Bench to Bedside: Innovations and Challenges in CAR-T Cell Therapy Manufacturing and Regulation.- Chapter 9: Combining CAR T Cells with Immunotherapies to Enhance Treatment Effectiveness.- Chapter 10: Next-Generation CARs and Beyond: Synthetic Biology and Logic-Gated in Next-Generation CARs.- Chapter 11: Regulatory landscape and challenges in CAR-T cell therapy development and clinical trials.- Chapter 12: Personalized CAR T-Cell Therapy: Tailoring to Patient-Specific Tumors.